Free shipping on all orders over $ 500

Nedaplatin

Cat. No. M3955
Nedaplatin Structure
Synonym:

NDP

Size Price Availability Quantity
10mg USD 90  USD90 In stock
50mg USD 330  USD330 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Nedaplatin is a platinum complex that has potent antineoplastic activity. Nedaplatin produces less nausea, vomiting and nephrotoxicity than other platinum-containing products.NDP was developed as a second generation platinum complex.Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP).Nedaplatin (NDP) is a second-generation platinum complex with reduced nephrotoxicity that may substitute for CDDP or even surpass it for use in combination with other drugs.

Protocol (for reference only)
Cell Experiment
Cell lines Human SCLC cell line SBC-3 and human NSCLC cell line PC-14
Preparation method The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, exposing cells to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; then pipetting the cells six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. Defining the IC50 as the drug concentration required for a 50% reduction in the number of cells.Carrying four or five independent experiments out for each. Treating the cells either by simultaneous exposure to the two drugs or by sequential exposure to Nedaplatin followed by irinotecan (Nedaplatin→irinotecan) and vice versa (irinotecan→Nedaplatin) for 3 hours to check the effect of the drug treatment schedule on the effect of the combination . For the sequential exposure treatment, exposing cells to the first drug for 3 hours, ished in fresh medium once, and then immediately exposing to the second drug for 3 hours. Culturing the treated cells in drug-free medium until evaluation
Concentrations 0.005 μg/mL, 0.01 μg/mL, 0.025 μg/mL, 0.05 μg/mL, 0.1 μg/mL, 0.25 μg/mL, and 0.5 μg/mL
Incubation time 6 days
Animal Experiment
Animal models Tumor-bearing athymic BALB/c nude mice with Ma44 or NCI-H460 cells
Formulation Saline
Dosages 10 mg/kg or 20 mg/kg
Administration Administered via i.v.
Chemical Information
Molecular Weight 303.17
Formula C2H8N2O3Pt
CAS Number 95734-82-0
Form Solid
Solubility (25°C) DMSO
water 10mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Kanzawa F, et al. Clin Cancer Res. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

[2] Uchida N, et al. Eur J Cancer. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model.

[3] Uchida N, et al. Anticancer Res. Antitumor efficacy of nedaplatin, a novel platinum complex, with cyclophosphamide in murine and human tumor model.

Related DNA/RNA Synthesis Products
DTP3 TFA

DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor.

Mating Factor α (1-6)

Mating Factor α (1-6) is a mating factor produced by α-mating type cells of Saccharomyces cerevisiae and an acts as an inhibitor of the initiation of DNA synthesis in the cells.

Polynucleotide kinase

Polynucleotide Kinase is a DNA repair enzyme.

Tetrapeptide

Tetrapeptide, an analogue of α-MSH, induces melanin synthesis.

Branaplam hydrochloride

Branaplam hydrochloride is an orally active, brain-permeable, selective modulator of SMN2 splicing, with an EC50 of 20 nM for SMN, and enhances full-length SMN protein and prolongs survival in a mouse model of severe spinal muscular atrophy (SMA). Branaplam hydrochloride also inhibits hERG with an IC50 of 6.3 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Nedaplatin, NDP supplier, DNA/RNA Synthesis, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.